{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T17:24:27Z","timestamp":1760549067396},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2011,3,1]],"date-time":"2011-03-01T00:00:00Z","timestamp":1298937600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ophthalmologe"],"published-print":{"date-parts":[[2011,3]]},"DOI":"10.1007\/s00347-010-2264-y","type":"journal-article","created":{"date-parts":[[2011,3,21]],"date-time":"2011-03-21T14:31:20Z","timestamp":1300717880000},"page":"222-229","source":"Crossref","is-referenced-by-count":8,"title":["Intravitreale Implantate"],"prefix":"10.1007","volume":"108","author":[{"given":"S.","family":"Winterhalter","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Ruokonen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.H.","family":"van der Velden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"U.","family":"Pleyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.M.","family":"Joussen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,3,23]]},"reference":[{"key":"2264_CR1","unstructured":"Bordello F (2010) 12-month evaluation of dexamethasone intravitreal Implant in patients with macular edema due to central retinal vein occlusion. Abstract 560 EURETINA Paris"},{"key":"2264_CR2","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/j.ophtha.2010.02.022","volume":"117","author":"Brown","year":"2010","unstructured":"Brown DM, Campochiaro PA, Singh RP (2010) Ranibizumab for macular edema following central retinal vein occlusion. Six-month primary end point results of a phase III study. Ophthalmology 117:1124\u20131133","journal-title":"Ophthalmology"},{"key":"2264_CR3","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1001\/archopht.126.9.1191","volume":"126","author":"Callanan","year":"2008","unstructured":"Callanan D, Jaffe G, Martin D et al (2008) Treatment of posterior uveitis with a fluocinolone acetonide implant. Arch Ophthalmol 126(9):1191\u20131201","journal-title":"Arch Ophthalmol"},{"key":"2264_CR4","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/j.ophtha.2010.02.021","volume":"117","author":"Campochiaro","year":"2010","unstructured":"Campochiaro PA, Heier JS, Feiner L (2010) Ranibizumab for macular edema following branch retinal vein occlusion. Six-month primary end point results of a phase III study. Ophthalmology 117:1102\u20131112","journal-title":"Ophthalmology"},{"key":"2264_CR5","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1001\/archophthalmol.2010.21","volume":"128","author":"Haller","year":"2010","unstructured":"Haller JA, Kuppermann BD, Blumenkranz MS et al (2010) Randomized controlled trial of an intravitreous dexamethasone drug delivery system in patients with diabetic macular edema. Arch Ophthalmol 128(3):289\u2013296","journal-title":"Arch Ophthalmol"},{"key":"2264_CR6","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/j.ophtha.2010.03.032","volume":"117","author":"Haller","year":"2010","unstructured":"Haller JA, Bandello F, Belfort R et al (2010) Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology 117(6):1134\u20131146","journal-title":"Ophthalmology"},{"key":"2264_CR7","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1097\/ICU.0b013e3282f03d42","volume":"18","author":"Imrie","year":"2007","unstructured":"Imrie FR, Dick AD (2007) Biologics in the treatment of uveitis. Curr Opin Ophthalmology 18:481\u2013486","journal-title":"Curr Opin Ophthalmology"},{"key":"2264_CR8","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/S0002-9394(00)00659-0","volume":"130","author":"Jabs","year":"2000","unstructured":"Jabs DA, Rosenabum JT, Foster CS et al (2000) Perspective: Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol 130(4):492\u2013513","journal-title":"Am J Ophthalmol"},{"key":"2264_CR9","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/j.ophtha.2006.02.021","volume":"113","author":"Jaffe","year":"2006","unstructured":"Jaffe GJ, Martin D, Callanan D et al (2006) Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirty-four-week results of a multicenter randomized clinical study. Ophthalmology 113(6):1020\u20131027","journal-title":"Ophthalmology"},{"key":"2264_CR10","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1001\/archopht.125.3.309","volume":"125","author":"Kuppermann","year":"2007","unstructured":"Kuppermann BD, Blumenkranz MS, Haller JA et al (2007) Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema. Arch Ophthalmol 125(3):309\u2013317","journal-title":"Arch Ophthalmol"},{"key":"2264_CR11","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1001\/archopht.1992.01080140115038","volume":"110","author":"Kwak","year":"1992","unstructured":"Kwak HW, D\u2019Amico DJ (1992) Evaluation of the retinal toxicity and pharmacokinetics of dexamethasone after intravitreal injection. Arch Ophthalmol 110:259\u2013266","journal-title":"Arch Ophthalmol"},{"key":"2264_CR12","doi-asserted-by":"crossref","unstructured":"Lowder C, Belfort R, Lightman S (2011) Dexamethasone intravitreal implant for noninfectious intermdiate or posterior uveitis. Arch Opthalmol (published online January 10). doi: 10.1001\/archophthalmol.2010.339","DOI":"10.1001\/archophthalmol.2010.339"},{"key":"2264_CR13","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.ophtha.2009.11.027","volume":"117","author":"Pavesio","year":"2010","unstructured":"Pavesio C, Zierhut M, Bairi K et al (2010) Evaluation of an intravitreal fluocinolone acetonide implant versus standard systemic therapy in noninfectious posterior uveitis. Ophthalmology 117(3):567\u2013575","journal-title":"Ophthalmology"},{"key":"2264_CR14","doi-asserted-by":"crossref","first-page":"403","DOI":"10.3109\/09273940903072443","volume":"17","author":"Sharma","year":"2009","unstructured":"Sharma SM, Nestel AR, Lee RWJ et al (2009) Clinical review: Anti-TNF\u03b1 therapies in uveitis: perspective on 5 years of clinical experience. Ocul Immunol Inflamm 17(6):403\u2013414","journal-title":"Ocul Immunol Inflamm"},{"key":"2264_CR15","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1159\/000318021","volume":"224","author":"Taylor","year":"2010","unstructured":"Taylor SR, Isa H, Joshi L et al (2010) New developments in corticosteroid therapy for uveitis. Ophthalmologica 224(1):46\u201353","journal-title":"Ophthalmologica"},{"key":"2264_CR16","unstructured":"Welty DF, Robinson MR, Kuppermann BD et al (2008) Pharmacokinetics of intravitreally administered dexamethasone posterior-segment drug delivery system. WOC abstract 6791"},{"key":"2264_CR17","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/j.ajo.2008.12.033","volume":"147","author":"Williams","year":"2009","unstructured":"Williams GA, Haller JA, Kuppermann BD et al (2009) Dexamethasone posterior-segment drug delivery system in the treatment of macular edema resulting from uveitis or Irvine-Gass syndrome. Am J Ophthalmol 147(6):1048\u20131054","journal-title":"Am J Ophthalmol"}],"container-title":["Der Ophthalmologe"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00347-010-2264-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00347-010-2264-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00347-010-2264-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,9]],"date-time":"2019-06-09T06:40:17Z","timestamp":1560062417000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00347-010-2264-y"}},"subtitle":["Wirkstoff- und \u201eHoffnungstr\u00e4ger\u201c?"],"short-title":[],"issued":{"date-parts":[[2011,3]]},"references-count":17,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,3]]}},"alternative-id":["2264"],"URL":"https:\/\/doi.org\/10.1007\/s00347-010-2264-y","relation":{},"ISSN":["0941-293X","1433-0423"],"issn-type":[{"value":"0941-293X","type":"print"},{"value":"1433-0423","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,3]]}}}